Oral glycoprotein IIb/IIIa antagonists in coronary artery disease

Chew, D.; Bhatt, Deepak L.

doi:10.1007/s11886-001-0012-2

Cited by 14 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even within the group of integrin α v β 3 blocking molecules, biological outcomes might differ from one inhibitor to another. In fact, in the field of integrin biology, small molecule inhibitors often produce results distinct from those of antibodies [35–39]. As another example, tumstatin, a naturally occurring proteolytic product of collagen cleavage, seems to block α v β 3 leading to decreased proliferation and increased apoptosis of endothelial cells [40, 41].…”

Section: Integrin αVβ3 In Angiogenesismentioning

confidence: 99%

“…Activation-induced complex was demonstrated in [48, 55], direct binding of extracellular domains was shown in [47], cross linking by transglutaminases was demonstrated in [87], possible coupling by the common ligands suggested based on [92]. Physiological and pathological consequences of the interplay between these two receptors are discussed in [35, 46, 56]. b The diagram shows possible sequence of molecular events involved in interaction between VEGFR2 and α V β 3 .…”

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

2009

View full text Add to dashboard Cite

The cross-talk between receptor tyrosine kinases and integrin receptors are known to be crucial for a number of cellular functions. On endothelial cells, an interaction between integrin α v β 3 and VEGFR2 seems to be particularly important process during vascularization. Importantly, the functional association between VEGFR2 and integrin α v β 3 is of reciprocal nature since each receptor is able to promote activation of its counterpart. This mutually beneficial relationship regulates a number of cellular activities involved in angiogenesis, including endothelial cell migration, survival and tube formation, and hematopoietic cell functions within vasculature. This article discusses several possible mechanisms reported by different labs which mediate formation of the complex between VEGFR-2 and α v β 3 on endothelial cells. The pathological consequences and regulatory events involved in this receptor cross-talk are also presented.

show abstract

Section: Integrin αVβ3 In Angiogenesismentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

2009

View full text Add to dashboard Cite

show abstract

“…Notably, in the latter study, the effect on neutrophil migration was reversed after discontinuation of clopidogrel treatment. In patients undergoing percutaneous coronary intervention, clopidogrel pretreatment reduced platelet inflammatory markers expression (CD40 ligand and CD62 P-selectin) and also attenuated the increased 30-day risk of death or MI associated with elevated baseline levels of CRP and attenuated the periprocedural rise of CRP [42][43][44].…”

Section: Clopidogrel: Pharmacologymentioning

confidence: 99%

Clopidogrel for the secondary prevention of stroke

Diener¹,

Ringleb²,

Savi

2005

Expert Opinion on Pharmacotherapy

110

112

View full text Add to dashboard Cite

Patients suffering a transient ischaemic attack (TIA) or ischaemic stroke (IS) have a high risk of recurrence. The inhibition of platelet function is effective in the reduction of secondary vascular events in patients with TIA or stroke. This is true for acetylsalicylic acid (ASA), clopidogrel, ticlopidine and the combination of ASA plus slow-release dipyridamole. This overview analyses the results of recent trials and presents ongoing or future trials with clopidogrel as well as the combination of clopidogrel plus ASA. Clopidogrel is superior to ASA in the prevention of vascular events in patients with IS, myocardial infarction (MI) or peripheral arterial disease (PAD). The difference is highest for high-risk patients such as diabetics, patients who underwent coronary bypass surgery and patients with a remote prior history of ischaemic events. A prediction model is presented which allows the identification of patients in whom clopidogrel is superior to ASA for the secondary prevention of stroke. The combination of clopidogrel and ASA is better than ASA alone in patients undergoing coronary stent implantations and patients with unstable angina or non-Q-wave MI. In high-risk patients with TIA or stroke, the addition of ASA to clopidogrel is not superior to ASA monotherapy but results in a higher rate of bleeding complications. The long-term combination therapy is currently investigated in several large trials in > 30,000 patients, with a large number of stroke patients.

show abstract

“…An example of a more precisely targeted treatment option is abciximab, a monoclonal antibody to GPIIb/IIIa working against receptors both in platelets and in tumours [28]. However, the usefulness of this type of blockade in long‐term therapy has been disappointing in trials on patients with coronary disease [29], even though preliminary data on patients with cancer are encouraging [30].…”

Section: Discussionmentioning

confidence: 99%

Genetic variation in platelet integrin α_IIbβ₃ (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma

Kallio¹,

Mikkelsson

Tammela

et al. 2006

BJU International

View full text Add to dashboard Cite

a cross-sectional survey of 128 men treated for RCC (55 with disseminated disease and 73 with a local disease), they were genotyped using DNA extracted from freshly drawn blood, and central clinical data were recorded. RESULTSThe frequency of possessing the GPIIIaPl A2 allele among patients with metastatic RCC was 43.6%, and with local disease was 24.7% ( P = 0.024). The frequencies of the different alleles of the GIB-IX-V, C3550T and GPIa/IIa C807T polymorphisms did not differ between the groups. In a stepwise logistic regression (metastatic vs local RCC) the Pl A2 allele remained a significant risk factor, with an odds ratio of 2.7 (95% confidence interval, 1.1-6.5; P = 0.02). CONCLUSIONThe prothrombotic Pl A2 allele of platelet fibrinogen receptor GPIIb/IIIa increased the risk of metastases in RCC in men.

show abstract

Oral glycoprotein IIb/IIIa antagonists in coronary artery disease

Cited by 14 publications

References 40 publications

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

Clopidogrel for the secondary prevention of stroke

Genetic variation in platelet integrin α_IIbβ₃ (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma

Contact Info

Product

Resources

About

Oral glycoprotein IIb/IIIa antagonists in coronary artery disease

Cited by 14 publications

References 40 publications

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis

Clopidogrel for the secondary prevention of stroke

Genetic variation in platelet integrin αIIbβ3 (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma

Contact Info

Product

Resources

About

Genetic variation in platelet integrin α_IIbβ₃ (GPIIb/IIIa) and the metastatic potential of renal cell carcinoma